2242 related articles for article (PubMed ID: 8261570)
1. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.
Frei E; Holden SA; Gonin R; Waxman DJ; Teicher BA
Cancer Chemother Pharmacol; 1993; 33(2):113-22. PubMed ID: 8261570
[TBL] [Abstract][Full Text] [Related]
2. Development of alkylating agent-resistant human tumor cell lines.
Teicher BA; Frei E
Cancer Chemother Pharmacol; 1988; 21(4):292-8. PubMed ID: 3370736
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
4. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
6. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
Teicher BA; Holden SA; Herman TS; Sotomayor EA; Khandekar V; Rosbe KW; Brann TW; Korbut TT; Frei E
Int J Cancer; 1991 Jan; 47(2):252-60. PubMed ID: 1846350
[TBL] [Abstract][Full Text] [Related]
8. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Ayash L; Korbut T; Herman TS; Teicher BA
Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
[TBL] [Abstract][Full Text] [Related]
9. Alkylating agent resistance: in vitro studies with human cell lines.
Frei E; Cucchi CA; Rosowsky A; Tantravahi R; Bernal S; Ervin TJ; Ruprecht RM; Haseltine WA
Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2158-62. PubMed ID: 3856890
[TBL] [Abstract][Full Text] [Related]
10. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
11. Reversal of drug-resistance by exposure of mcf-7 or mcf-7 cddp human breast-carcinoma cells to sr-4233 or etanidazole under hypoxic conditions.
Kusumoto T; Teicher B; Holden S; Coleman C; Liu S; Sotomayor E
Int J Oncol; 1993 Aug; 3(2):205-11. PubMed ID: 21573349
[TBL] [Abstract][Full Text] [Related]
12. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.
Teicher BA; Chatterjee D; Liu JT; Holden SA; Ara G
Cancer Chemother Pharmacol; 1993; 32(4):315-9. PubMed ID: 8324874
[TBL] [Abstract][Full Text] [Related]
13. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin.
Belvedere G; Imperatori L; Damia G; Tagliabue G; Meijer C; de Vries EG; D'Incalci M
Eur J Cancer; 1996 Oct; 32A(11):2011-8. PubMed ID: 8943689
[TBL] [Abstract][Full Text] [Related]
15. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
Ara G; Kusumoto T; Korbut TT; Cullere-Luengo F; Teicher BA
Cancer Res; 1994 Mar; 54(6):1497-502. PubMed ID: 8137254
[TBL] [Abstract][Full Text] [Related]
16. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
17. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A
Cancer Chemother Pharmacol; 2000; 45(3):239-46. PubMed ID: 10663642
[TBL] [Abstract][Full Text] [Related]
18. Patterns of resistance and therapeutic synergism among alkylating agents.
Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
